| Publications | PubMed=2854303; DOI=10.1620/tjem.156.319
Nozawa Y., Abe M., Wakasa H., Ohno H., Fukuhara S., Kinoshita T., Osato T.
Establishment and characterization of an Epstein-Barr virus negative B-cell lymphoma cell line and successful heterotransplantation.
Tohoku J. Exp. Med. 156:319-330(1988) PubMed=3338018; DOI=10.1002/1097-0142(19880201)61:3<483::AID-CNCR2820610313>3.0.CO;2-L
Abe M., Nozawa Y., Wakasa H., Ohno H., Fukuhara S.
Characterization and comparison of two newly established Epstein-Barr virus-negative lymphoma B-cell lines. Surface markers, growth characteristics, cytogenetics, and transplantability.
Cancer 61:483-490(1988) PubMed=8558920
Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G.
The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.
Leukemia 10:142-149(1996) DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001) PubMed=15028022; DOI=10.1111/j.1440-1827.2004.01612.x
Kamimura K., Hojo H., Abe M.
Characterization of expression of protein kinase C isozymes in human B-cell lymphoma: relationship between its expression and prognosis.
Pathol. Int. 54:224-230(2004) PubMed=20054396; DOI=10.1038/nature08638; PMCID=PMC2845535
Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. 3rd, Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A., Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M., Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.-C., Pierce S.K., Staudt L.M.
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Nature 463:88-92(2010) PubMed=21179087; DOI=10.1038/nature09671; PMCID=PMC5024568
Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W.-M., Lim K.-H., Kohlhammer H., Xu W.-H., Yang Y.-D., Zhao H., Shaffer A.L. 3rd, Romesser P.B., Wright G., Powell J.I., Rosenwald A., Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.-C., Staudt L.M.
Oncogenically active MYD88 mutations in human lymphoma.
Nature 470:115-119(2011) PubMed=23257783; DOI=10.1038/leu.2012.367
Wenzel S.-S., Grau M., Mavis C., Hailfinger S., Wolf A., Madle H., Deeb G., Dorken B., Thome M., Lenz P., Dirnhofer S., Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
Leukemia 27:1381-1390(2013) PubMed=26787899; DOI=10.1073/pnas.1524677113; PMCID=PMC4747717
Dekker J.D., Park D., Shaffer A.L. 3rd, Kohlhammer H., Deng W., Lee B.-K., Ippolito G.C., Georgiou G., Iyer V.R., Staudt L.M., Tucker H.O.
Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
Proc. Natl. Acad. Sci. U.S.A. 113:E577-E586(2016) PubMed=29416618; DOI=10.18632/oncotarget.20378; PMCID=PMC5787470
Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C., Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr., Pham L.V.
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Oncotarget 9:346-360(2018) PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004
Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H., Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Clin. Cancer Res. 24:3967-3980(2018) PubMed=30165192; DOI=10.1016/j.canlet.2018.08.020
Qu C.-J., Kunkalla K., Vaghefi A., Frederiksen J.K., Liu Y.-D., Chapman J.R., Blonska M., Bernal-Mizrachi L., Alderuccio J.P., Lossos I.S., Landgraf R., Vega-Vazquez F.
Smoothened stabilizes and protects TRAF6 from degradation: a novel non-canonical role of smoothened with implications in lymphoma biology.
Cancer Lett. 436:149-158(2018) PubMed=31510952; DOI=10.1186/s12885-019-6129-8; PMCID=PMC6739943
Takashima Y., Yoshimura T., Kano Y., Hayano A., Hondoh H., Ikenaka K., Yamanaka R.
Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells.
BMC Cancer 19:910.1-910.11(2019) |
|---|
